BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37119285)

  • 1. Recent Advances in Targeting the Urokinase Plasminogen Activator with Nanotherapeutics.
    Kumar AA; Vine KL; Ranson M
    Mol Pharm; 2023 Jun; 20(6):2766-2780. PubMed ID: 37119285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The urokinase-type plasminogen activator system and its role in tumor progression].
    Kugaevskaya EV; Gureeva TA; Timoshenko OS; Solovyeva NI
    Biomed Khim; 2018 Nov; 64(6):472-486. PubMed ID: 30632975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of urokinase plasminogen activator and its receptor in metastasis and invasion of neuroblastoma.
    Li P; Gao Y; Ji Z; Zhang X; Xu Q; Li G; Guo Z; Zheng B; Guo X
    J Pediatr Surg; 2004 Oct; 39(10):1512-9. PubMed ID: 15486896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
    Pulukuri SM; Gondi CS; Lakka SS; Jutla A; Estes N; Gujrati M; Rao JS
    J Biol Chem; 2005 Oct; 280(43):36529-40. PubMed ID: 16127174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
    Yoshizawa K; Nozaki S; Kitahara H; Kato K; Noguchi N; Kawashiri S; Yamamoto E
    Oncol Rep; 2011 Dec; 26(6):1555-60. PubMed ID: 21833477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the tumor-associated urokinase-type plasminogen activation system: effects of high-level synthesis of soluble urokinase receptor in ovarian and breast cancer cells in vitro and in vivo.
    Magdolen V; Krüger A; Sato S; Nagel J; Sperl S; Reuning U; Rettenberger P; Magdolen U; Schmitt M
    Recent Results Cancer Res; 2003; 162():43-63. PubMed ID: 12790320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
    Holst-Hansen C; Johannessen B; Høyer-Hansen G; Rømer J; Ellis V; Brünner N
    Clin Exp Metastasis; 1996 May; 14(3):297-307. PubMed ID: 8674284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy.
    Sidenius N; Blasi F
    Cancer Metastasis Rev; 2003; 22(2-3):205-22. PubMed ID: 12784997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor.
    Zheng Q; Tang ZY; Xue Q; Shi DR; Song HY; Tang HB
    J Cancer Res Clin Oncol; 2000 Nov; 126(11):641-6. PubMed ID: 11079728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies.
    Rabbani SA; Xing RH
    Int J Oncol; 1998 Apr; 12(4):911-20. PubMed ID: 9499455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor - β1 (TGF-β1) and potential effects on migration and invasion.
    Magnussen SN; Hadler-Olsen E; Costea DE; Berg E; Jacobsen CC; Mortensen B; Salo T; Martinez-Zubiaurre I; Winberg JO; Uhlin-Hansen L; Svineng G
    BMC Cancer; 2017 May; 17(1):350. PubMed ID: 28526008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo.
    Reuning U; Sperl S; Kopitz C; Kessler H; Krüger A; Schmitt M; Magdolen V
    Curr Pharm Des; 2003; 9(19):1529-43. PubMed ID: 12871066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urokinase-type plasminogen activator system and breast cancer (Review).
    Han B; Nakamura M; Mori I; Nakamura Y; Kakudo K
    Oncol Rep; 2005 Jul; 14(1):105-12. PubMed ID: 15944776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
    Costantini V; Sidoni A; Deveglia R; Cazzato OA; Bellezza G; Ferri I; Bucciarelli E; Nenci GG
    Cancer; 1996 Mar; 77(6):1079-88. PubMed ID: 8635127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The urokinase plasminogen activator system in breast cancer invasion and metastasis.
    Tang L; Han X
    Biomed Pharmacother; 2013 Mar; 67(2):179-82. PubMed ID: 23201006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urokinase plasminogen activator/urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38alpha mitogen-activated protein kinase activity.
    Huang S; New L; Pan Z; Han J; Nemerow GR
    J Biol Chem; 2000 Apr; 275(16):12266-72. PubMed ID: 10766865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer.
    Duggan C; Maguire T; McDermott E; O'Higgins N; Fennelly JJ; Duffy MJ
    Int J Cancer; 1995 May; 61(5):597-600. PubMed ID: 7768629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation and role of urokinase plasminogen activator in vascular remodelling.
    Tkachuk V; Stepanova V; Little PJ; Bobik A
    Clin Exp Pharmacol Physiol; 1996 Sep; 23(9):759-65. PubMed ID: 8911711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical localization of a urokinase-type plasminogen activator system in squamous cell carcinoma of the oral cavity: association with mode of invasion and lymph node metastasis.
    Nozaki S; Endo Y; Kawashiri S; Nakagawa K; Yamamoto E; Yonemura Y; Sasaki T
    Oral Oncol; 1998 Jan; 34(1):58-62. PubMed ID: 9659521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulinlike growth factor-I-mediated migration and invasion of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen activator receptor.
    Bauer TW; Fan F; Liu W; Johnson M; Parikh NU; Parry GC; Callahan J; Mazar AP; Gallick GE; Ellis LM
    Ann Surg; 2005 May; 241(5):748-56; discussion 756-8. PubMed ID: 15849510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.